Free tool
Drug Trial Radar: Gastroenterology and liver
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
3
Active, not recruiting, industry sponsors, Gastroenterology and liver, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed197
3 trials
Showing 1 to 3, recently updated first.
- A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)Pivotal-lookingActive, not recruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06836609 · 118 participants · Start Apr 28, 2025 · Primary completion Aug 17, 2027
Drug: ALN-CIDEB; Placebo · For: Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis
Sites: Chandler, Arizona; Tucson, Arizona; London, United Kingdom · 4 sites in all
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and OverweightPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06151964 · 166 participants · Start Sep 29, 2023 · Primary completion Jan 29, 2027
Drug: AZD9550; placebo and 1 more · For: Overweight and Obesity
Sites: Graz, Austria; Vienna, Austria; Surrey, Canada · 15 sites in all
- A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver FatActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07214870 · 29 participants · Start Oct 8, 2025 · Primary completion May 14, 2027
Drug: NNC4005-001; Placebo · For: Fatty Liver Disease
Sites: Montreal, Canada
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.